View article

Elisa Gremese, Gianfranco Ferraccioli

2013

medicine

65

94-100

Tofacitinib for rheumatoid arthritis Page 1 Correspondence 1812 www.thelancet.com Vol 381 May 25, 2013 same chance of getting results as those with BMI <30, since BMI can affect the efficacy of some TNFi.Additionally, we need to know whether a poor response to other biological drugs used as firstline therapy, such as abatacept or tocilizumab, will be rescued to the same extent with tofacitinib. This will be particularly important for tocilizumab because tofacitinib seems to have biological effects comparable to those of tocilizumab–rapid onset of pharmacological effect and adverse events, such as dislipidaemia. We declare that we have no conflicts of interest. *Elisa Gremese, Gianfranco Ferraccioli [email protected] Catholic University of the Sacred Heart, Rome 00168, Italy 1 Burmester GR, Bland R, Charles-Shoeman C, et al. Tofacitinib (CP 690-550) in combination with methotrexate in patients with …